Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection

Paolo S. Silva, Ravinder J. Singh, Sophie J. Bakri, Ramil S. Lising, Darby E. Santiago, Harvey S. Uy

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Purpose: To determine vitreous concentrations of triamcinolone acetonide(TA) following transseptal injection. Methods: TA (40 mg/l ml) was administered at varying intervals prior to vitrectomy. Vitreous samples from 18 patients were obtained. TA concentrations were quantified using HPLC-MS. Results: Vitreous levels of TA were detected in all samples (range 0.64-168.0 ng/ml). The interval from injection to sampling ranged from 0.5-20 days. Tmax was attained at 0.5 days. TA concentrations were negatively correlated with scleral thickness (P = 0.0184) and depot location (P = 0.0230) but not with PVD status (P = 0.9633). Conclusion: Significant vitreous concentrations of TA are achieved after a single transseptal injection. Scleral thickness, depot location and time influence vitreous TA levels.

Original languageEnglish (US)
Pages (from-to)216-220
Number of pages5
JournalOcular Immunology and Inflammation
Issue number3
StatePublished - Jun 2009


  • Corticosteroids
  • Peribulbar injection
  • Transseptal injection
  • Triamcinolone acetonide
  • Vitreous concentration

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology


Dive into the research topics of 'Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection'. Together they form a unique fingerprint.

Cite this